Ganz PA, Bandos H, Spanic T, Friedman S, et al. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. J Clin Oncol 2024 Feb 1:JCO2301214. doi: 10.1200/JCO.23.01214.
PMID: 38301187